Why the study?
Does flow cytometric VASP 239 phosphorylation assessment accurately detect clopidogrel responsiveness compared to Western blot and aggregometry in CHD patients?
Population
21 clopidogrel-treated coronary heart disease (CHD) patients and 28 healthy volunteers (Total n=49).
Comparison
Flow cytometric assessment of VASP 239… vs Western blot and aggregometry
Design
Cross-sectional
Authors
Loading...
Flow cytometric VASP assay may lack sensitivity for clopidogrel responsiveness; leaves open its reliability versus Western blot in CHD.
Does flow cytometric VASP 239 phosphorylation assessment accurately detect clopidogrel responsiveness compared to Western blot and aggregometry in CHD patients?
Flow cytometric VASP 239 phosphorylation assay lacks sensitivity to detect clopidogrel responsiveness compared to Western blot, suggesting caution when using it to classify patients as low-responders.
Hézard et al. (2005) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: